Newsroom

December 14, 2011
Fate Therapeutics announces the appointment of William H. Rastetter as Chairman and Interim CEO
November 7, 2011
Naurex's Novel Antidepressant GLYX-13 Recognized As One of Windhover's 2011 Top 10 Neuroscience Projects to Watch
June 27, 2011
Redwood Bioscience Secures Funding for Optimized Conjugate Drug Development
May 11, 2011
Naurex Completes $18 Million Series A Financing
May 9, 2011
Takeda Ventures makes strategic investment in Fate Therapeutics –Joins strategic investor syndicate of Fate that includes four pharmaceutical companies
April 11, 2011
Heptares and Takeda Initiate Drug Discovery Collaboration Focused on GPCR linked to CNS Disorders
March 14, 2011
CellCentric Closes First Tranche of Series B Financing
January 6, 2011
Symphogen Raises €100 Million in Private Equity Round

October 19,2010
Patrys initiates clinical studies in melanoma patients with PAT-SM6, a natural human antibody against GRP78
October 08,2010
Takeda and Envoy Form Schizophrenia Research Alliance
September 16, 2010
Symphogen Announces Publication of Data on the Manufacture of Polyclonal Antibodies Developed Using Sympress™ Technology
August 31,2010
CellCentric's Scientific Founder Awarded Royal Medal
Feb 22, 2010
CellCentric Licenses Novel Epigenetic Discovery Programme to Takeda Pharmaceutical Company, Ltd
Feb 18, 2010
Domainex Ltd Announces Investment From Takeda Research Investment, Inc
Jan 26, 2010
Envoy Therapeutics, Inc. today announced that it has entered into a multi-year research collaboration agreement with an affiliate of Merck & Co., Inc. to discover novel diabetes and obesity drug targets. For full details, please click here here.
Jan 25, 2010
CellCentric, the biotechnology company unlocking epigenetic control mechanisms, has an ongoing research relationship with Prof. Wolf Reik at the Babraham Institute, Cambridge. New work from his lab published today in Nature, highlights the substantial degree to which DNA demethylation occurs in early mammalian development and that AID is a critical component of the process. It builds upon Wolf Reik's earlier work on the biochemistry of AID's activities in cells. For full details, please click here here.

Nov 11, 2009
Envoy Therapeutics, Inc., a newly formed drug discovery company, today announced that it has secured a loan from Takeda Research Investment (TVI) which Envoy may elect to convert to Envoy preferred stock should the company complete a second private equity financing. TVI will receive certain rights from Envoy related to a specific therapeutic field while scientists at the two companies craft a broad scientific research alliance. For full details, please click here.
Oct 14, 2009
Envoy Therapeutics, a new drug discovery company based in Jupiter FL, announces the successful closing of its first financing, an $8 million private placement of the company's Series A Preferred Stock. Led by 5AM Ventures, other investors participating in the financing included Takeda Research Investment and Roche Venture Fund. For full details, please click here.
Jun 02, 2009
CellCentric announces that the company is hosting a conference and celebration of Imprinting and Epigenetics, at the University of Cambridge on September 4-6th 2009. For full details, please click here.